COVID-19 and seasonal influenza are caused by entirely different viruses that share a talent for infecting the respiratory tract and producing symptoms that can feel remarkably similar in the first day or two of illness. Both cause fever, cough, body aches, and fatigue, and both spread mainly through respiratory droplets and aerosols. But the similarities run thinner than most people assume. The viruses differ in how they replicate, how quickly they spread, what they do once they reach organs beyond the lungs, and how dangerous they are at a population level. Understanding where the two diseases diverge matters for recognizing what you’re dealing with and knowing when to worry.
Two Very Different Viruses
Influenza A is caused by a segmented, negative-sense RNA virus belonging to the Orthomyxoviridae family, with a relatively small genome of about 13.5 kilobases split across eight gene segments. SARS-CoV-2, the virus behind COVID-19, is a positive-sense RNA coronavirus in the Coronaviridae family, with a much larger genome of roughly 30 kilobases carried on a single strand.1PMC. SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments – Section: 2. Virology of Influenza A Virus and SARS-CoV-2 That size difference has a practical consequence: SARS-CoV-2 carries its own proofreading enzyme, which corrects copying errors during replication. Influenza lacks this proofreader, and its mutation rate per replication cycle is roughly 24 times higher than that of SARS-CoV-2 in lab conditions.2PubMed Central. Comparison of genome replication fidelity between SARS-CoV-2 and influenza A virus in cell culture
Paradoxically, SARS-CoV-2 still manages to evolve quickly in the real world. Its enormous number of infections globally gave it a huge pool in which to accumulate advantageous mutations, and its variants have appeared more frequently and more independently across geographies than influenza A variants typically do.3PubMed Central. SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments Influenza, meanwhile, relies on a different trick for reinventing itself: because its genome is segmented, two different flu strains infecting the same cell can swap entire gene segments, producing a dramatically new virus in one step. That mechanism, called reassortment, is what drives the periodic emergence of pandemic flu strains and is the reason flu vaccines have to be reformulated every year based on predictions about which strains will circulate.
How the Symptoms Overlap and Where They Split
At the onset, both illnesses look a lot alike. Fever, cough, sore throat, nasal congestion, body aches, and general fatigue appear in both COVID and flu patients. In hospitalized adults, flu tends to present with more prominent classical respiratory symptoms. One study of hospitalized patients during the 2025–2026 respiratory season in Poland found cough in about 71% of influenza patients compared to under 50% of those with COVID-19, while fever and muscle and joint pain were also more common in flu.4PubMed Central. Comparison of the Clinical Course of Viral Respiratory Infections in Hospitalized Patients During the 2025/2026 Season in Poland Other symptoms like nausea, vomiting, diarrhea, and sore throat occurred at similar rates in both groups.
The most distinctive COVID symptom has been loss of smell or taste. A large matched-population study found that the three-month incidence of smell and taste disorders was about 11 times higher following COVID-19 than following influenza.5PubMed. Comparison of the incidence of smell and taste disorders between influenza and COVID-19 While newer variants cause this less frequently than the original strains did, it remains far more associated with COVID than with any seasonal flu. It is worth noting that newer Omicron-lineage variants have made this symptom less common, narrowing the gap somewhat, but the overall pattern holds.
Neurological Differences
Loss of smell and taste are actually part of a broader picture: SARS-CoV-2 has a particular affinity for the nervous system that goes well beyond what flu typically does. A systematic review comparing COVID-19 with other respiratory viral infections, including flu, found that COVID shows a higher incidence of neurological complications, a broader range of nervous system involvement, and a tendency toward severe events like stroke and encephalopathy.6PubMed Central. Neurological Complications Associated With COVID-19 Compared to Other Viral Infections: A Systematic Review of Current Evidence The flu can cause neurological symptoms too, particularly in severe cases and in children (febrile seizures being the classic example), but the scope and severity of neurological involvement seen with COVID is in a different league.
This matters for the “long” version of each illness as well. While post-viral fatigue syndromes can follow influenza, the constellation of lingering neurological symptoms grouped under long COVID, including brain fog, persistent smell disturbances, and autonomic dysfunction, appears to be more common and more persistent after SARS-CoV-2 infection than after flu.
Blood Clots and Vascular Damage
One of the more alarming differences between the two infections is what happens to blood vessels. SARS-CoV-2 directly infects endothelial cells, the cells lining blood vessels, triggering inflammation and a cascade of clotting abnormalities including increased antiphospholipid antibodies and heightened platelet activity. These changes are more pronounced in COVID-19 than in influenza.7JAMA. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients
The result is a substantially higher rate of both arterial events (like strokes and heart attacks) and venous events (like deep vein thrombosis and pulmonary embolism) in hospitalized COVID patients compared to hospitalized flu patients. Research suggests that two mechanisms are at work simultaneously: the virus drives clot formation directly in the small vessels of the lungs, and it also promotes the conventional process of clot formation in deep veins that can then travel to the lungs.8PubMed Central. Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients Flu can cause clotting complications too, but both the frequency and the diversity of mechanisms are notably greater with COVID.
Heart Inflammation
Myocarditis, or inflammation of the heart muscle, has been a headline concern with COVID-19. After adjusting for demographic and clinical risk factors, COVID-19 diagnosis was independently associated with an increased risk of myocarditis in the year following infection compared to influenza diagnosis, with the risk particularly elevated in males under 30.9PubMed Central. Epidemiology of myocarditis following COVID-19 or influenza and use of diagnostic assessments Influenza can also trigger myocarditis, but the association is weaker and less consistently documented in large datasets. For young men especially, this represents one of the more meaningful clinical differences between the two infections.
Overall Mortality
Early in the pandemic, the comparison between COVID and flu deaths became politically charged. The data have settled the question clearly: COVID-19 is substantially more lethal at a population level. A meta-analysis covering more than 12.8 million COVID-19 patients and nearly 2.9 million influenza patients found that COVID was associated with significantly higher 30-day all-cause mortality, with the adjusted odds ratio at 1.76 overall. The gap was even wider in working-age adults (18 to 64), where COVID’s mortality risk was nearly three times that of flu, and among hospitalized patients, where it was about 2.5 times higher.10International Journal of Infectious Diseases. Increased 30-day mortality risk in COVID-19 compared with seasonal influenza
A separate analysis looking at cumulative deaths across U.S. states found that for the country as a whole, it took roughly 17 years of combined influenza and pneumonia deaths to equal just three years of COVID-19 pandemic deaths. Only Hawaii came close to parity, where three years of COVID deaths roughly matched three years of flu and pneumonia deaths. In four states, more than 21 years of flu deaths were needed to match the COVID toll.11PubMed Central. Is Covid-19 Mortality “Like the Flu”? A Cumulative Death Rates Comparison These numbers reflect the pandemic period from 2020 to early 2023, and the gap has narrowed as population immunity has grown, but the comparison puts to rest the early-pandemic talking point that COVID was “just the flu.”
How Things Differ in Children
Here the picture flips in an unexpected way. Multiple studies have found that COVID-19 tends to run a milder course than influenza in children. A review of clinical comparisons found that children hospitalized with influenza had higher rates of ICU admission, need for oxygen therapy, mechanical ventilation, and death compared to children hospitalized with COVID-19.12PubMed Central. Comparison of the Clinical and Laboratory Features of COVID and Influenza in Children Inflammatory markers were also consistently lower in the COVID group.
One study comparing hospitalized children directly found that the influenza group had dramatically higher rates of cough, fever, muscle pain, vomiting, and rapid breathing. The flu group also needed ICU care far more often and had a mortality rate of about 15% compared to roughly 1% in the COVID group.13PubMed Central. Does Covid‐19 in children have a milder course than Influenza? This is an important nuance for parents: while COVID is deadlier than flu in adults, especially older adults and those with underlying conditions, the reverse has often been true for kids. Influenza has long been a serious pediatric threat, and the arrival of COVID did not change that.
Incubation and Transmission Timing
Flu hits faster. The incubation period for influenza is estimated at about 1.3 to 1.5 days, while the Omicron variants of SARS-CoV-2 have an incubation period ranging from roughly 2 to 5.6 days.14PubMed Central. Risk period for transmission of SARS-CoV-2 and seasonal influenza: a rapid review That means flu symptoms show up sooner after exposure, and the window between feeling fine and feeling sick is shorter. The practical consequence is that by the time you realize you have the flu, you may have already passed the peak period of being contagious to others.
Both viruses are transmissible before symptoms appear, but the window of pre-symptomatic spread has been a bigger factor for COVID, partly because its longer incubation period creates more days of unknowing infectiousness. The same rapid review found that at least 80% of secondary transmissions for both flu and Omicron occur within about five days after the primary case develops symptoms, even though viral shedding continues for days beyond that point. Shedding, in other words, is not a reliable marker for when you’re actually spreading the virus to others.
Secondary Bacterial Infections
A common complication of respiratory viruses is that they soften up the lungs for bacterial invaders. This is a well-established feature of influenza: secondary bacterial pneumonia was a leading killer in both the 1918 pandemic and in seasonal flu outbreaks. Interestingly, the overall rates of secondary bacterial infection and bacterial co-infection in COVID-19 patients have been lower than those typically associated with influenza.15PubMed Central. Coronavirus disease 2019 (COVID-19): Secondary bacterial infections and the impact on antimicrobial resistance during the COVID-19 pandemic
That said, when secondary bacterial pneumonia does develop in critically ill COVID patients, it carries a serious prognosis. Research on intubated COVID patients found that secondary bacterial pneumonia was significantly associated with mortality, and that suppressed immune signaling in the lungs, potentially driven by corticosteroid treatment used to manage COVID inflammation, appeared to allow opportunistic bacteria to expand.16PubMed Central. Microbial dynamics and pulmonary immune responses in COVID-19 secondary bacterial pneumonia So while COVID creates fewer bacterial complications overall than flu, the ones that do occur can be dangerous, and ironically one of the treatments for COVID itself may contribute to the problem.
Testing and How to Tell Them Apart at Home
You cannot reliably distinguish COVID from flu based on symptoms alone, especially in the first couple of days. The good news is that combination rapid antigen tests that check for both SARS-CoV-2 and influenza A and B from a single nasal swab are now widely available. An evaluation of one such combo test found sensitivity above 93% for all three targets (COVID, flu A, and flu B) and specificity of 100% when compared against PCR.17PubMed Central. Performance evaluation of a SARS-CoV-2 and influenza A/B combo rapid antigen test In children tested in an emergency department setting, a triple rapid test (covering COVID, flu, and RSV) showed sensitivity above 88% for all three viruses with perfect specificity.18Infectious Diseases Now. Diagnostic accuracy of a rapid antigen triple test (SARS-CoV-2, respiratory syncytial virus, and influenza) using anterior nasal swabs versus multiplex RT-PCR in children in an emergency department
Knowing which virus you have matters because the antiviral treatments differ. Oseltamivir (Tamiflu) works against influenza but does nothing for COVID. Nirmatrelvir-ritonavir (Paxlovid) works against COVID but not flu. Both work best when started within the first day or two of symptoms, which is why rapid testing has real clinical value rather than just being a curiosity.
Seasonality and Why Both Peak in Winter
Flu follows a well-established seasonal cycle, peaking in colder months in temperate climates. COVID initially circulated year-round during the early pandemic waves, but research has found that the factors driving flu seasonality, including ultraviolet radiation levels, temperature, and relative humidity, appear to influence COVID-19 spread in similar ways.19PubMed Central. Comparable seasonal pattern for COVID-19 and flu-like illnesses Studies in the Netherlands specifically found that higher humidity was associated with reduced incidence of both influenza and COVID-19.20PubMed Central. Environmental risk factors of airborne viral transmission: Humidity, Influenza and SARS-CoV-2 in the Netherlands As COVID has settled into a more endemic pattern, winter surges have become increasingly predictable, though summer waves still happen, particularly when new variants emerge.
Genetic Susceptibility Is Not Shared
You might assume that if you’re genetically predisposed to getting sicker from one respiratory virus, you’d be similarly vulnerable to the other. That turns out not to be the case. A large genetic study found that of 24 identified risk variants for severe COVID-19, only one was also associated with influenza, and the direction of its effect was opposite: the version of the gene that increased COVID risk actually decreased flu risk. The overall genetic correlation between susceptibility to the two infections was modest, suggesting that the biological pathways driving vulnerability to each are largely distinct.21Nature Genetics. Genetic risk factors for COVID-19 and influenza are largely distinct This finding makes sense given how differently the two viruses interact with the immune system and with the cells they infect.
Cross-Reactive Immunity Between the Two
Despite the genetic separation, there is a curious immunological connection. Researchers found that a majority of people who had never been exposed to SARS-CoV-2, somewhere between 62% and 73% in one study, already carried antibodies that recognized a specific peptide shared between the two viruses. Flu vaccination actually boosted both antibody and T cell responses to this shared peptide in healthy adults, though not in elderly individuals.22iScience. Pre-existing cross-reactive immunity to key peptides of SARS-CoV-2 and influenza A can affect COVID-19 pandemic dynamics Separately, studies in Vietnam confirmed the presence of cross-reactive immunity against SARS-CoV-2 in blood samples collected years before the pandemic began, likely due to prior infections with common cold coronaviruses rather than flu specifically.23International Journal of Infectious Diseases. Pre-existing cross-reactive neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants, Vietnam
Whether this pre-existing cross-reactivity meaningfully protected people from severe COVID remains an open question. It likely helped to some degree during the earliest waves, when no one had been vaccinated or previously infected, by priming parts of the immune response. But it was clearly not enough to prevent the massive toll of the pandemic, and its relevance diminishes further with every new variant that reshapes the virus’s surface proteins.
How SARS-CoV-2 Hides from the Immune System
One reason COVID proved so devastating is that SARS-CoV-2 has evolved sophisticated mechanisms for silencing the body’s early-warning alarm system. Research on the Alpha and Delta variants showed that these lineages progressively improved their ability to suppress innate immune signaling in infected cells, limiting the production of cytokines and chemokines that would normally recruit immune defenders. Both variants also evolved resistance to interferon, the body’s primary antiviral signaling molecule.24PubMed Central. SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells Influenza also interferes with interferon signaling, but the breadth and layered nature of SARS-CoV-2’s immune evasion toolkit is distinctive. This helps explain why COVID can progress silently for several days before the immune system mounts a vigorous, and sometimes dangerously overblown, inflammatory response.